One day, young recluse Tomoro Tenma’s Sapotama turns into a Digimon, a hyperactive lizard called Gekkomon, starting Tomoro ...

The newest Digimon anime is finally getting an English dub, and it could help the series revitalize the brand's popularity ...

Patients on Eli Lilly’s next-generation obesity shot lost nearly 30% of their body weight on average in a trial that tracked them for a little more than a year—a result that’s far better than the most ...

Eli Lilly and Company delivered best-in-class weight loss data for retatrutide, reinforcing its dominance in obesity and diabetes therapeutics. Retatrutide achieved up to 28.7% average weight loss and ...

Eli Lilly LLY0.50%increase; green up pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

An Eli Lilly drug candidate designed to hit three metabolic targets led patients to lose an average of 28.7% of their body weight in a late-stage clinical trial, setting a new high mark in the ...

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial. Eli Lilly’s triple ...

Eli Lilly announced a $6 billion investment in a manufacturing campus in northern Alabama to boost production of its next-generation medicines for obesity and metabolic diseases. This project is part ...